Bidell Monique R, Palchak Melissa, Mohr John, Lodise Thomas P
Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
Merck & Co., Inc., Kenilworth, New Jersey, USA.
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3170-3. doi: 10.1128/AAC.02505-15. Print 2016 May.
This analysis of nearly 10,000 hospital-associated urinary tract infection (UTI) episodes due to Escherichia coli showed that fluoroquinolone and third-generation-cephalosporin resistance rates were 34.5% and 8.6%, respectively; the rate of concurrent resistance to both agents was 7.3%. Fluoroquinolone resistance rates exceeded 25% regardless of geographic location or hospital characteristics. The findings suggest that fluoroquinolones should be reserved and third-generation cephalosporins be used with caution as empirical agents for hospitalized patients with UTIs due to E. coli.
这项对近10000例由大肠杆菌引起的医院相关尿路感染（UTI）病例的分析表明，氟喹诺酮类和第三代头孢菌素的耐药率分别为34.5%和8.6%；对这两种药物同时耐药的比例为7.3%。无论地理位置或医院特征如何，氟喹诺酮类耐药率均超过25%。研究结果表明，对于因大肠杆菌引起UTI的住院患者，应保留氟喹诺酮类药物，并谨慎使用第三代头孢菌素作为经验性用药。
